Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003430 · ClinicalTrials.gov registry record · Phase 1

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

A Phase 1 study of Head and Neck Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT00003430: Completed Phase 1 study of Head and Neck Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00003430 is a Phase 1 study of Head and Neck Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003430, a Phase 1 study of Head and Neck Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or refractory solid tumors.

Interventions

  • DRUG L-778,123

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1998-04
Est. Completion 2000-04
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00003430 record still lists

NCT00003430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which L-778,123 is the first listed.

NCT00003430 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00003430 about?

NCT00003430 is a clinical study titled "L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or refractory solid tumors.

What is the current status of trial NCT00003430?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1998-04. Estimated completion is 2000-04.

What conditions does trial NCT00003430 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT00003430?

The interventions under investigation include: L-778,123 (DRUG).

Who is sponsoring clinical trial NCT00003430?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003430 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003430's enrollment target sits among peer trials

40 142nd of 250 higher than 99 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003430, the US trial registry maintained by the National Library of Medicine. NCT00003430 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.